Joint Filing AgreementJoint Filing Agreement • February 14th, 2024 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, par value $0.0001 per share, of Pliant Therapeutics, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2024 • Redmile Group, LLC • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 par value per share, of Gritstone bio, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 16th, 2021 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, at $0.0001 par value per share, of Stoke Therapeutics, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2019 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 par value per share, of GlycoMimetics, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2022 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 par value per share, of Aprea Therapeutics, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 16th, 2021 • Redmile Group, LLC • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 par value per share, of Atara Biotherapeutics, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2024 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.01 par value per share, of ImmunoGen, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2019 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.01 par value per share, of ImmunoGen, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
LOCK-UP AGREEMENTLock-Up Agreement • July 27th, 2023 • Redmile Group, LLC • Pharmaceutical preparations
The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Neoleukin Therapeutics, Inc., a Delaware corporation (“Parent”), has entered into an Agreement and Plan of Merger, dated as of July 17, 2023 (as the same may be amended from time to time, the “Merger Agreement”) with Project North Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, and Neurogene Inc., a Delaware corporation (the “Company”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement.
FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENTForm of Company Stockholder Support Agreement • July 27th, 2023 • Redmile Group, LLC • Pharmaceutical preparations • Delaware
This Support Agreement (this “Agreement”) is made and entered into as of July 17, 2023, by and among Neurogene Inc., a Delaware corporation (the “Company”), Neoleukin Therapeutics, Inc., a Delaware corporation (“Parent”), and the undersigned stockholder (the “Stockholder”) of the Company. Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2023 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.01 par value per share, of ImmunoGen, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 16th, 2021 • Redmile Group, LLC • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 par value per share, of Gritstone Oncology, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2022 • Redmile Group, LLC • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.01 par value per share, of Ayala Pharmaceuticals, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
PARENT STOCKHOLDER SUPPORT AGREEMENTParent Stockholder Support Agreement • July 27th, 2023 • Redmile Group, LLC • Pharmaceutical preparations • Delaware
This Support Agreement (this “Agreement”) is made and entered into as of July 17, 2023, by and among Neurogene Inc., a Delaware corporation (the “Company”), Neoleukin Therapeutics, Inc., a Delaware corporation (“Parent”), and the undersigned stockholder (the “Stockholder”) of Parent. Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement.
FORM OF LOCK-UP AGREEMENTRedmile Group, LLC • August 2nd, 2021 • Services-commercial physical & biological research • New York
As Representatives of the several Underwriters listed in Schedule 1 to the Underwriting Agreement referred to below c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179
Joint Filing AgreementJoint Filing Agreement • February 16th, 2021 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.01 par value per share, of Deciphera Pharmaceuticals, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2023 • Redmile Group, LLC • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.00001 par value per share, of Krystal Biotech, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 16th, 2021 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 par value per share, of Yumanity Therapeutics, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2023 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 par value per share, of Hookipa Pharma Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENTCompany Stockholder Support Agreement • July 27th, 2023 • Redmile Group, LLC • Pharmaceutical preparations • Delaware
This Support Agreement (this “Agreement”) is made and entered into as of July 17, 2023, by and among Neurogene Inc., a Delaware corporation (the “Company”), Neoleukin Therapeutics, Inc., a Delaware corporation (“Parent”), and the undersigned stockholder (the “Stockholder”) of the Company. Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement.
Joint Filing AgreementJoint Filing Agreement • January 14th, 2022 • Redmile Group, LLC • Retail-drug stores and proprietary stores
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto, the “Schedule 13D”) relating to the common stock, $0.001 par value per share, of MedAvail Holdings, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • November 16th, 2018 • Redmile Group, LLC • Surgical & medical instruments & apparatus
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the common stock, $0.001 par value per share, of Vapotherm, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2023 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 par value per share, of Pliant Therapeutics, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 8th, 2023 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 par value per share, of Ayala Pharmaceuticals, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2023 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, par value $0.0001 per share, of Entrada Therapeutics, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2024 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, at $0.0001 par value per share, of Stoke Therapeutics, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2024 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.0001 par value per share, of RAPT Therapeutics, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • October 15th, 2020 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto, the “Schedule 13D”) relating to the common stock, $0.0001 par value per share, of Shattuck Labs, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
FATE THERAPEUTICS, INC. 3535 General Atomics Court, Suite 200 San Diego, CA 92121Redmile Group, LLC • August 2nd, 2018 • Biological products, (no disgnostic substances)
This letter will confirm our agreement with you in connection with your purchase of shares of common stock and Class A preferred stock of Fate Therapeutics, Inc. (the “Company”). In connection with the sale of the Company’s common stock and Class A preferred stock pursuant to the Securities Purchase Agreement of even date herewith among the Company, affiliates of and funds managed by Redmile Group, LLC (the “Investor”) and certain other purchasers (the “Purchase Agreement”), the Investor will be entitled to the following contractual rights, in addition to the other rights specifically provided to all stockholders.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2024 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.000001 par value per share, of Neurogene Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2020 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Ordinary Shares, €0.05 par value per share, of uniQure N.V., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2023 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock of Zymeworks Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2022 • Redmile Group, LLC • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock of ADC Therapeutics SA, which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 8th, 2023 • Redmile Group, LLC • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.01 par value per share, of Old Ayala, Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
Joint Filing AgreementJoint Filing Agreement • February 16th, 2021 • Redmile Group, LLC • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.01 par value per share, of Beam Therapeutics Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.
